A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long-Term Safety, Tolerability, Pharmocokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
This Study is
No Longer Enrolling
The TEASE studies (Tolerability and Effects of ALK-001 in Stargardt Disease) are a series of clinical trials evaluating an investigational drug called ALK-001 in people who have Stargardt Disease. There are no FDA-approved treatments to slow the progression of Stargardt Disease. Research studies are conducted to determine if an investigational drug is safe and effective.
MoreChild to Adult
Participants in this study must be at least 8 years old and diagnosed with Stargardt Disease, as confirmed by genetic testing, and must meet all other eligibility criteria.
Treatment
University of Colorado Hospital
Protocol Number: 19-1103
More information available at ClinicalTrials.gov: NCT02402660
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers